Glucocorticoid-induced osteoporosis: 2013 update

Reumatismo

Volumn 66, Issue 2, 2014, Pages 144-152

  Mazzantini, Maurizio ^a   Di Munno, O ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Glucocorticoid induced osteoporosis

Indexed keywords

25 HYDROXYVITAMIN D; ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; BUDESONIDE; CALCIUM; DENOSUMAB; GLUCOCORTICOID; IBANDRONIC ACID; METHOTREXATE; PARATHYROID HORMONE[1-34]; PLACEBO; PREDNISOLONE; PREDNISONE; RISEDRONIC ACID; VITAMIN D; ZOLEDRONIC ACID;

BONE DENSITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONNECTIVE TISSUE DISEASE; CORTICOSTEROID INDUCED OSTEOPOROSIS; CORTICOSTEROID THERAPY; DRUG HALF LIFE; FRACTURE RISK ASSESSMENT TOOL; HIP FRACTURE; HUMAN; INFLAMMATORY BOWEL DISEASE; INVOLUTIONAL OSTEOPOROSIS; KIDNEY FAILURE; KYPHOPLASTY; NONHUMAN; OPTIMAL DRUG DOSE; PATHOGENESIS; PATIENT COMPLIANCE; PERCUTANEOUS VERTEBROPLASTY; POSTMENOPAUSE OSTEOPOROSIS; PREGNANT WOMAN; REVIEW; RHEUMATIC DISEASE; RHEUMATIC POLYMYALGIA; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SECONDARY HYPERPARATHYROIDISM; SECONDARY OSTEOPOROSIS; SPINE FRACTURE; CHEMICALLY INDUCED; OSTEOPOROSIS;

GLUCOCORTICOIDS; HUMANS; OSTEOPOROSIS;

EID: 84905168728     PISSN: 00487449     EISSN: 22402683     Source Type: Journal    
DOI: 10.4081/reumatismo.2014.787     Document Type: Review

References (78)

1. Mazzantini M, Talarico R, Doveri M, Consensi A, Cazzato M, Bazzichi L, et al. Incident comorbidity among patients with rheumatoid arthritis treated or not with low-dose glucocorticoids: a retrospective study. J Rheumatol. 2010; 37: 2232-6.
2. Kanis JA, Johansson H, Oden A, Johnell O, de Laet C, Melton III LJ, et al. A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res. 2004; 19: 893-9.
3. van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int. 2002; 13: 777-87.
4. Natsui K, Tanaka K, Suda M, Yasoda A, Sakuma Y, Ozasa A, et al. High-dose glucocorticoid treatment induces rapid loss of trabecular bone mineral density and lean body mass. Osteoporos Int. 2006; 17: 105-8.
5. Adachi JD, Saag KG, Delmas PD, Liberman UA, Emkey RD, Seeman E, et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum. 2001; 44: 202-11.
6. Cohen S, Levy RM, Keller M, Boling E, Emkey RD, Greenwald M, et al. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum. 1999; 42: 2309-18.
7. Cooper C, Coupland C, Mitchell M. Rheumatoid arthritis, corticosteroid therapy and hip fracture. Ann Rheum Dis. 1995; 54: 49-52.
8. van Staa TP, Geusens P, Pols HA, de Laet C, Leufkens HG, Cooper C. A simple score for estimating the long-term risk of fracture in patients using oral glucocorticoids. QJM. 2005; 98: 191-8.
9. van Staa TP. The pathogenesis, epidemiology and management of glucocorticoid-induced osteoporosis. Calcif Tissue Int. 2006; 79: 129-37.
10. Lems WF. Bisphosphonates and glucocorticoids: effects on bone quality. Arthritis Rheum. 2007; 56: 3518-22.
11. Mazziotti G, Angeli A, Bilezikian JP, Canalis E, Giustina A. Glucocorticoid-induced osteoporosis: an update. Trends Endocrinol Metab. 2206; 17: 144-9.
12. Canalis E, Mazziotti G, Giustina A, Bilezikian JP. Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int. 2007; 18: 1319-28.
13. Toth M, Grossman A. Glucocorticoid-induced osteoporosis: lesson's from Cushing's syndrome. Clin Endocrinol. 2013: 79: 1-11.
14. Hofbauer LC, Rauner M. Minireview: Live and let die: molecular effects of glucocorticoids on bone cells. Mol Endocrinol. 2009; 23: 1525-31.
15. Davidson ZE, Walker KZ, Truby H. Do gluco- corticoids alter vitamin D status? A systematic review with meta-analyses of observational studies. J Clin Endocrinol Metab. 2012; 97: 738-44.
16. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2011; 96: 1911-30.
17. Avioli LV, Birge SJ, Lee SW. Effects of prednisone on vitamin D metabolism in man. J Clin Endocrinol Metab. 1968; 28: 1341-46.
18. Zhou C, Assem M, Tay JC, Watkins PB, Blumberg B, Schuetz EG, et al. Steroid and xenobiotic receptor and vitamin D receptors crosstalks mediats CYP24 expression and drug-induced osteomalacia. J Clin Invest. 2006; 116: 1703-12.
19. Wortsman J, Matsuuoka LY, Chen TC, Lu Z, Holick MF. Decreased bioavailability of vitamin D in obesity. Am J Clin Nutr. 2000: 72: 690-3.
20. Weinstein RS. Glucocoticoid-induced bone disease. N Engl J Med. 2011; 365: 62-70.
21. Tauchmanova L, Pivonello R, De Martino MC, Rusciano A, De Leo M, Ruosi C, et al. Effects of sex steroids on bone in women with subclinical or overt endogenous hupercortisolism. Eur J Endocrinol. 2007; 157: 359-66.
22. Pivonello R, De Leo M, Vitale P, Cozzolino A, Simeoli C, De Martino MC, et al. Pathophysiology of diabetes mellitus in Cushing's syndrome. Neuroendocrinol. 2010; 92: 77-81.
23. Thrailkill KM, Lumkin CK Jr, Bunn RC, Kemp SF, Fowlkes JL. Is insulin an anabolic agent in bone? Dissecting the diabetic bone for clues. Am J Phys Endocrinol Metab. 2005; 289: E735-45.
24. Giustina A, Wehrenberg WB. The role of gluco- corticoids in the regulation of growth hormone secretion. Mechanism and clinical significance. Trends Endocrinol Metab. 2002; 8: 306-11.
25. Malerba M, Bossoni S, Radaeli A, Mori E, Bonadonna S, Giustina A, et al. Growth hormone response to growth hormone-releasing hormone is reduced in adult asthmatic patients receiving long-term inhaled corticosteroid treatment. Chest. 2005; 127: 515-21.
26. Delany AM, Durant D, Canalis E. Glucocorticoid suppression of IGF I transcription in osteoblasts. Mol Endocrinol. 2001; 15: 1781-9.
27. Compston J. Management of glucocorticoid- induced osteoporosis. Nat Rev Rheumatol. 2012; 6: 82-8.
28. Liu Y, Porta A, Peng X, Gengaro K, Cunningham EB, Li H, et al. Prevention of glucocorticoid-induced apoptosis in osteocytes and osteoblasts by calbindin-D28K. J Bone Miner Res. 2004; 19: 479-90.
29. Thornberry NA, Labeznik Y. Caspases: enemies within. Science. 1998; 281: 1312-6.
30. Shi XM, Blair HC, Yang X, McDonald JM, Cao X. Tandem repeat of C/EBP binding sites mediates PPARg2 gene transcription in glucocorticoid-induced adipocyte differentiation. J Cell Biochem. 2000; 76: 518-27.
31. Zhang W, Yang N, Shi XM. Regulation of mesenchymal stem cell osteogenic differentiation by glucocorticoid-induced leucine zipper. J Biol Chem. 2008; 283: 4723-29.
32. Ohnaka K, Tanabe M, Kawate H, Nawata H, Takayanagi R. Glucocorticoid suppresses the canonical Wnt signal in cultured human osteoblasts. Biochem Biophys Res Commun. 2005; 329: 177-81.
33. Smith E, Frenkel B. Glucocorticoids inhibit the transcriptional activity of LEF/TCF in differentiating osteoblasts in a glycogen synthase kinase-3-dependent and-independent manner. J Biol Chem. 2005; 280: 2388-94.
34. Krishnan V, Bryant HU, MacDougald OA. Regulation of bone mass by Wny signaling. J Clin Invest. 2006; 116: 1202-9.
35. Yao W, Cheng Z, Busse C, Pham A, Nakamura MC, Lane NE. Glucocorticoid excess in mice results in early activation of osteoclastogenesis and adipogenesis and prolonged suppression of osteogenesis. Arthritis Rheum. 2008; 58: 1674-86.
36. Hayashi K, Yamaguchi T, Yano S, Kanazawa I, Yamauchi M, Yamamoto M, et al. BMP/Wnt antagonists are upregulated by dexamethasone in osteoblasts and reversed by alendronate and PTH: potential therapeutic targets for gluco- corticoid-induced osteoporosis. Biochem Biophys Res Commun. 2009; 379: 261-6.
37. Wang FS, Ko JY, Yeh DW, Ke HC, Wu HL. Modulation of Dickkopf-1 attenuates glucocorticoid induction of osteoblast apoptosis, adipocytic differentiation, and bone mass loss. Endocrinology. 2008; 149: 1793-801.
38. Den Uyl, Bultink IE, Lems WF. Advances in glucocorticoid-induced osteoporosis. Curr Rheumatol Rep. 2011; 13: 233-40.
39. Almeida M, Han L, Ambrogini E, Weinstein RS, Manolagas S. Glucocorticoids and tumor necrosis factor a increase oxidatibe stress and suppress Wnt signaling in osteoblasts. J Biochem Chem. 2011; 286: 44326-35.
40. Manolagas S. From estrogen-centric to aging and oxidative stress: a revise perspective o the pathogenesis of osteoporosis. Endocr Rev. 2010; 31: 266-300.
41. Jilka RL, Almeida M, Amdrogini E, Han L, Roberson PK, Weinstein RS, et al. Decreased oxidative stress and greater bone anabolism in the aged, when compared to the young, murine skeleton with parathyroid hormone administration. Aging Cell. 2010; 9: 851-67.
42. Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocyets by glucocoticoids: potential mechanism of their deleterious effects on bone. J Clin Invest. 1998; 102: 274-82.
43. Bonewald LF. The amazing osteocyte. J Bone Miner Res. 2011; 26: 229-38.
44. O'Brien CA, Jia D, Plotkin LI, Bellido T, Powers CC, Stewart SA, et al. Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology. 2004; 145: 1835-41.
45. Weinstein RS, Wan C, Liu Q, Wang Y, Almeida M, O'Brien CA, et al. Endogenous glucocorticoids decrease skeletal angiogenesis, vascularity, hydration, and strength in aged mice. Aging Cell. 2010; 9: 147-61.
46. Hofbauer LC, Gori F, Riggs BL, Lacey DL, Dunstan CR, Spelsberg TC, et al. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanism of glucocorticoid-induced osteoporosis. Endocrinology. 1999; 140: 4382-9.
47. Rubin J, Biskobing DM, Jadhav, Fan D, Nanes MS, Perkins S, et al. Dexamethasone promotes expression of membrane-bound macrophage colony-stimulating factors in murine osteoblast-like cells. Endocrinology. 1998; 139: 1006-12.
48. Dovio A, Perazzolo L, Saba L, Termine A, Capobianco M, Bertolotto A, et al. High-dose glucocorticoids increase serum levels of soluble IL-6 receptor alpha and its ratio to soluble gp130: an additional mechanism for early increased bone resorption. Eur J Endocrinol. 2006; 154: 745-51.
49. Takuma A, Kaneda T, Sato T, Ninomiya S, Kumegawa M, Hakeda Y. Dexamethasone enhances osteoclast formation synergistically with transforming growth factor-beta by stimulating the priming of osteoclast progenitors for differentiation into osteoclasts. J Biol Chem. 2003; 278: 44667-74.
50. Knauper V, Will H, Lopez-Otin C, Smith B, Atkinson SJ, Stanton H, et al. Cellular mechanisms for human procollagenase-3 activation. J Biol Chem. 1996; 271: 17124-31.
51. Freje JMP, Diez-Itza I, Balbin M, et al. Molecular cloning and expression of collagenase 3, a novel human matrix metalloproteinase produced by breast carcinomas. J Biol Chem. 1994; 269: 16766-73.
52. Delany AM, Jeffrey JJ, Rydziel S, Canalis E. Cortisol increases interstitial collagenase expression in osteoblasts by post-transcriptional mechanism. J Biol Chem. 1995; 270: 26607-12.
53. Cooper MS. Sensitivity of bone to glucocorticoids. Clin Sci. 2004; 107: 11-23.
54. Barnes PJ. Glucocorticoids: current and future directions. Br J Pharmacol. 2011; 163: 29-43.
55. van Rossum EF, Voorhoeve PG, te Velde SJ, Koper JW, Delemarre-van de Waal HA, Kemper HC, et al. The ER22/23EK polymorphism in the glucocorticoid receptor gene is associated with a beneficial body composition and muscle strength in young adults. J Clin Endocrinol Metab. 2004; 89: 4004-9.
56. Draper N, Stewart PM. 11b-hydroxysteroid dehydrogenase and the pre-receptor regulation of corticosteroid hormone action. J Endocrinol. 2005; 186: 251-71.
57. Buttgereit F, Zhou H, Seibel M. Arthritis and endogenous glucocorticoids: the emerging role of the 11b-HSD enzymes. Ann Rheum Dis. 2008; 67: 1201-3.
58. Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med. 1998; 339: 292-9.
59. Cohen S, Levy RM, Keller M, Boling E, Emkey RD, Greenwald M, et al. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum. 1999; 42: 2309-18.
60. Reid DM, Hughes RA, Laan RF, Sacco-Gibson NA, Wenderoth DH, Adami S, et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. J Bone Miner Res. 2000; 15: 1006-13.
61. Wallach S, Cohen S, Reid DM, Hughes RA, Hosking DJ, Laan RF, et al. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int. 2000; 67: 277-85.
62. Hakala M, Kröger H, Valleala H, Hienonen-Kempas T, Lehtonen-Veromaa M, Heikkinen J, et al. Once-monthly oral ibandronate provides significant improvement in bone mineral density in postmenopausal women treated with glucocorticoids for inflammatory rheumatic diseases: a 12-month, randomized, double-blind, placebo-controlled trial. Scand J Rheumatol. 2012; 41: 260-6.
63. Reid DM, Devogelaer JP, Saag K, Roux C, Lau CS, Reginster JY, et al. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet. 2009; 373: 1253-63.
64. Saag KG, Shane E, Boonen S, Marín F, Donley DW, Taylor KA, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med. 2007; 357: 2028-39.
65. Curtis JR, Westfall AO, Allison JJ, Becker A, Casebeer L, Freeman A, et al. Longitudinal patterns in the prevention of osteoporosis in glucocorticoid-treated patients. Arthritis Rheum. 2005; 52: 2485-94.
66. Feldstein AC, Elmer PJ, Nichols GA, Herson M. Practice patterns in patients at risk for glucocorticoid-induced osteoporosis. Osteoporos Int. 2005; 16: 2168-74.
67. Grossman JM, Gordon R, Ranganath VK, Deal C, Caplan L, Chen W, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res. 2010; 62: 1515-26.
68. Lekawasam S, Adachi JD, Agnusdei D, Bilezikian J, Boonen S, Borgström F, et al. A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos Int. 2012; 23: 2257-76.
69. Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int. 2008; 19: 385-97.
70. Kanis JA, McCloskey EV, Johansson H, Strom O, Borgstrom F, Oden A. Case finding for the management of osteoporosis with FRAX-assessment and intervention thresholds for the UK. Osteoporos Int. 2008; 19: 1395-408.
71. Kanis JA, Johansson H, Oden A, McCloskey EV. Guidance for the adjustment of FRAX according to the dose of glucocorticoids. Osteoporos Int. 2011; 22: 809-16.
72. National Osteoporosis Foundation. Clinician's guide to prevention and treatment of osteoporosis. Washington, DC, National Osteoporosis Foundation, 2010. http://nof.org/files/nof/public/content/file/344/upload/159.pdf
73. Weinstein RS. Clinical practice: glucocorticoid-induced bone disease. N Engl J Med. 2011; 365: 62-70.
74. Adachi JD, Saag KG, Delmas PD, Liberman UA, Emkey RD, Seeman E, et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum. 2001; 44: 202-11.
75. Saag KG, Shane E, Boonen S, Marín F, Donley DW, Taylor KA, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med. 2007; 357: 2028-39.
76. Weinstein RS, Jilka RJ, Roberson PK, Almeida M, Roberson PK, Manolagas SC. Intermittent parathyroid hormone administration prevents glucocorticoid-induced osteoblast and osteocyte apoptosis, decreased bone formation, and reduced bone strength in mice. Endocrinology. 2010; 151: 2641-9.
77. Dore RK, Cohen SB, Lane NE, Palmer W, Shergy W, Zhou L, et al. Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates. Ann Rheum Dis. 2010; 69: 872-5.
78. Syed MI, Patel NA, Jan S, Shaikh A, Grunden B, Morar K. Symptomatic refractures after vertebroplasty in patients with steroid-induced osteoporosis. AJNR Am J Neuroradiol. 2006; 27: 1938-43.